Почетна › Интерстицијалне болести плућа › Kalifornija
Kliničke studije za Интерстицијалне болести плућа u državi Kalifornija
22 studija za Интерстицијалне болести плућа traži učesnike na lokacijama u državi Kalifornija.
Gradovi u državi Kalifornija
Zvanični tekst studije (na engleskom)
A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis
- University of California Los Angeles, Los Angeles
Тражи се учесникФаза 3
Узраст 40 и старији · Оба пола · Ажурирано 13. 11. 2026. · NCT07201922A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
- University of Southern California, Los Angeles
- Cedars Sinai Medical Center, Los Angeles
- Paradigm Clinical Research Centers, LLC, San Diego
Тражи се учесникФаза 2
Узраст 40 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT06968845Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
- University of California - Los Angeles, Los Angeles
- University of Southern California, Los Angeles
- Stanford University, Stanford
Тражи се учесникОпсервациона студија
Узраст 21 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT01915511FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression
- University of Southern California, Los Angeles
- Newport Native MD, Inc, Newport Beach
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT07540988Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension
- HCA Riverside Community Hospital, Riverside
Тражи се учесник
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT06911632Study of TX000045 in Participants With Pulmonary Hypertension Due to Interstitial Lung Disease
- San Francisco, San Francisco
Тражи се учесникФаза 2
Узраст од 18 до 80 · Оба пола · Ажурирано 27. 10. 2026. · NCT07473700Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- USA007, Fresno
- USA010, Los Angeles
- USA023, Los Angeles
- и још 2
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 26. 10. 2026. · NCT07179380A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD
- David Geffen School of Medicine at UCLA, Los Angeles
- University of California, San Francisco, San Francisco
Тражи се учесникФаза 3
Узраст од 18 до 80 · Оба пола · Ажурирано 14. 10. 2026. · NCT07285655Remote Evaluation and Surveillance of Patients With Interstitial Lung Disease: Transforming ILD Care Delivery With Remote Monitoring
- University of California, San Francisco, San Francisco
Тражи се учесник
Узраст 18 и старији · Оба пола · Ажурирано 9. 10. 2026. · NCT07673237A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)
- University of California Davis Health, Rancho Cordova
Тражи се учесникФаза 2
Узраст од 18 до 80 · Оба пола · Ажурирано 8. 10. 2026. · NCT07175038A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)
- GSK Investigational Site, Los Angeles
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 9. 9. 2026. · NCT06716606A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
- GSK Investigational Site, Los Angeles
- GSK Investigational Site, Los Angeles
- GSK Investigational Site, Orange
- и још 2
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 8. 9. 2026. · NCT06572384A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
- GSK Investigational Site, Los Angeles
- GSK Investigational Site, Los Angeles
- GSK Investigational Site, Los Angeles
- и још 1
Тражи се учесникФаза 2/3
Узраст 18 и старији · Оба пола · Ажурирано 8. 9. 2026. · NCT05878717A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
- Clinical Research Site, Santa Barbara
- Clinical Research Site, Torrance
Тражи се учесникФаза 2
Узраст од 18 до 85 · Оба пола · Ажурирано 2. 9. 2026. · NCT07333183DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- Cedars-Sinai Medical Center, Los Angeles
- UC Davis Health Medical Center, Sacramento
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Оба пола · Ажурирано 26. 8. 2026. · NCT06388421Platform Clinical Study for Conquering Scleroderma
- Keck School of Medicine at USC Medical Center, Los Angeles
- Cedars-Sinai Medical Center, Los Angeles
- Stanford University Medical Center, Palo Alto
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 18. 8. 2026. · NCT06195072Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease
- University of California, San Francisco, San Francisco
Тражи се учесникФаза 2
Узраст 4 и старији · Оба пола · Ажурирано 22. 7. 2026. · NCT04925375Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
- Peter Morton Medical Building, Los Angeles
- NewportNativeMD, Inc., Newport Beach
- University of California Irvine Medical Center, Orange
- и још 4
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 13. 7. 2026. · NCT05943535TRANSPIRE: Lung Injury in a Longitudinal Cohort of Pediatric HSCT Patients
- University of California San Francisco, San Francisco
Тражи се учесникОпсервациона студија
До 24 година · Оба пола · Ажурирано 22. 6. 2026. · NCT04098445Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis
- Keck School of Medicine of USC, Los Angeles
Тражи се учесникФаза 2
Узраст 40 и старији · Оба пола · Ажурирано 12. 11. 2025. · NCT05975983Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
- aTyr Investigative Site, Los Angeles
- aTyr Investigative Site, San Diego
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 7. 5. 2025. · NCT05892614Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease
- University of California San Francisco, San Francisco
Тражи се учесникОпсервациона студија
Узраст од 18 до 90 · Оба пола · Ажурирано 3. 5. 2024. · NCT06397677Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.